A Dose-finding Study of Nedaplatin and Cyclophosphamide for Patients with Gynecological Malignancies

Background: Nedaplatin is a new analogue of cisplatin with similar efficacy but less renal toxicity. We investigated the appropriate dose of nedaplatin in combination with cyclophosphamide for patients with gynecological malignancies. Methods: Nine patients (five with ovarian cancer and four with uterine cervical cancer) were studied. Three patients received 60 mg/m 2 of nedaplatin combined with 500 mg/m 2 of cyclophosphamide every 4 weeks. Another three patients were each administered 80 or 100 mg/m 2 of nedaplatin with the same dose of cyclophosphamide. A total of 27 courses was given. Results: No patient needed dose reduction due to myelosuppression and no severe adverse events were observed. Conclusions: Treatment with 100 mg/m 2 of nedaplatin and 500 mg/m 2 of cyclophosphamide is feasible for patients with gynecological malignancies. However, phase II studies are needed to clarify the efficacy of this combination chemotherapy.